FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2580451850> ?p ?o ?g. }

• W2580451850 abstract "Abstract Abstract 3408 More than 80% of patients (pts) with CML who are treated with imatinib as first line therapy achieve a complete cytogenetic response (CCR), although approximately 20% of these pts may ultimately progress. The most common mechanism for loss of response is acquired resistance to imatinib due to the development of a point mutation in the ABL kinase domain of BCR-ABL that interferes with optimal imatinib binding. An alternatively spliced BCR-ABL mRNA with a 35 bp insertion between exons 8 and 9 was first described in 2008 (Laudadio, 2008: Lee, 2008); this results in a BCR-ABL protein with 10 novel amino acids inserted after amino acid 474 within the C- terminus of the kinase domain followed by a stop codon. However, clinical responses to imatinib, dasatinib, or nilotinib have not been previously described in patients with this mutation. We retrospectively identified 40 pts who had this mutation detected and describe their clinical outcomes. Of the 40 patients, 24 were male, and the median age was 50, (range 16–70). Six patients had received treatment prior to 2001, and all 40 patients began initial therapy with imatinib. Twenty nine pts had mutation testing done because of either disease progression or lack of response to imatinib and in 9 pts, the mutation was detected during retrospective analysis. Two pts had the mutation detected at the time of diagnosis (one is still on imatinib). Six pts had additional mutations detected simultaneously: E255V, E355G, E450G, T315I with F416L, T315I with E255K, and one with another insertion between exons 4 and 5. The median time from start of imatinib to insertion mutation detection was 36 months (range 0–189). Thirty of the 40 pts (75%) either did not tolerate (n=2) or progressed while on therapy with imatinib (n=28). Eleven pts remain on imatinib, although 5 are on doses of 600 mg/day or higher. Eighteen of the 30 pts (60%) who failed imatinib were changed to dasatinib as second line therapy; 10 of these (56%) did not respond and were changed to nilotinib as third line therapy. Ten of the 30 pts (30%) who did not respond to imatinib were changed to nilotinib as second line therapy; 3 pts achieved an MCR. In summary, this report provides the first clinical summary of pts with CML who have the 35 bp intron 8 insertion mutation. Although it is not clear whether this insertion mutation directly leads to imatinib resistance, given that 75% of pts progressed on standard dose imatinib, other alternative therapies should be considered once this mutation is detected. However, given the small numbers of pts treated with dasatinib or nilotinib as second line therapy, it is difficult to determine whether either has a superior effect. Results of biochemical and cellular studies comparing the relative sensitivity of the BCR-ABL 35 bp intron 8 insertion mutation to several ABL kinase inhibitors will be presented. Table 1. Response summary for patients with BCR-ABL 35 bp intron 8 insertion mutation. Number of patients (%) Failure or progression on first-line imatinib 30/40 (75%) Failure or progression on second-line dasatinib 10/18 (56%) Failure or progression on second-line nilotinib 7/10 (70%) Kinase domain mutation concurrently detected with 35 bp insertion mutation 6/40 (15%) Received non-TKI treatment prior to front-line imatinib 6/40 (15%) Disclosures: Berman: Novartis Inc: Research Funding. Kantarjian:Genzyme: Research Funding; Eisai: Research Funding. Druker:Molecular MD: Equity Ownership." @default.
• W2580451850 created "2017-02-03" @default.
• W2580451850 creator A5003194414 @default.
• W2580451850 creator A5015101485 @default.
• W2580451850 creator A5029672494 @default.
• W2580451850 creator A5030828526 @default.
• W2580451850 creator A5033023115 @default.
• W2580451850 creator A5055985698 @default.
• W2580451850 creator A5076224974 @default.
• W2580451850 creator A5090435894 @default.
• W2580451850 date "2010-11-19" @default.
• W2580451850 modified "2023-10-15" @default.
• W2580451850 title "Clinical Outcomes In Patients with Chronic Myelogenous Leukemia (CML) and the BCR-ABL 35 Base Pair (bp) Intron 8 Insertion Mutation." @default.
• W2580451850 doi "https://doi.org/10.1182/blood.v116.21.3408.3408" @default.
• W2580451850 hasPublicationYear "2010" @default.
• W2580451850 type Work @default.
• W2580451850 sameAs 2580451850 @default.
• W2580451850 citedByCount "1" @default.
• W2580451850 countsByYear W25804518502019 @default.
• W2580451850 crossrefType "journal-article" @default.
• W2580451850 hasAuthorship W2580451850A5003194414 @default.
• W2580451850 hasAuthorship W2580451850A5015101485 @default.
• W2580451850 hasAuthorship W2580451850A5029672494 @default.
• W2580451850 hasAuthorship W2580451850A5030828526 @default.
• W2580451850 hasAuthorship W2580451850A5033023115 @default.
• W2580451850 hasAuthorship W2580451850A5055985698 @default.
• W2580451850 hasAuthorship W2580451850A5076224974 @default.
• W2580451850 hasAuthorship W2580451850A5090435894 @default.
• W2580451850 hasConcept C104317684 @default.
• W2580451850 hasConcept C125418893 @default.
• W2580451850 hasConcept C126322002 @default.
• W2580451850 hasConcept C143998085 @default.
• W2580451850 hasConcept C170493617 @default.
• W2580451850 hasConcept C176944494 @default.
• W2580451850 hasConcept C2776960273 @default.
• W2580451850 hasConcept C2777413986 @default.
• W2580451850 hasConcept C2777583451 @default.
• W2580451850 hasConcept C2778461978 @default.
• W2580451850 hasConcept C2778729363 @default.
• W2580451850 hasConcept C2779536868 @default.
• W2580451850 hasConcept C3019892230 @default.
• W2580451850 hasConcept C36823959 @default.
• W2580451850 hasConcept C42362537 @default.
• W2580451850 hasConcept C501734568 @default.
• W2580451850 hasConcept C502942594 @default.
• W2580451850 hasConcept C54355233 @default.
• W2580451850 hasConcept C71924100 @default.
• W2580451850 hasConcept C86803240 @default.
• W2580451850 hasConceptScore W2580451850C104317684 @default.
• W2580451850 hasConceptScore W2580451850C125418893 @default.
• W2580451850 hasConceptScore W2580451850C126322002 @default.
• W2580451850 hasConceptScore W2580451850C143998085 @default.
• W2580451850 hasConceptScore W2580451850C170493617 @default.
• W2580451850 hasConceptScore W2580451850C176944494 @default.
• W2580451850 hasConceptScore W2580451850C2776960273 @default.
• W2580451850 hasConceptScore W2580451850C2777413986 @default.
• W2580451850 hasConceptScore W2580451850C2777583451 @default.
• W2580451850 hasConceptScore W2580451850C2778461978 @default.
• W2580451850 hasConceptScore W2580451850C2778729363 @default.
• W2580451850 hasConceptScore W2580451850C2779536868 @default.
• W2580451850 hasConceptScore W2580451850C3019892230 @default.
• W2580451850 hasConceptScore W2580451850C36823959 @default.
• W2580451850 hasConceptScore W2580451850C42362537 @default.
• W2580451850 hasConceptScore W2580451850C501734568 @default.
• W2580451850 hasConceptScore W2580451850C502942594 @default.
• W2580451850 hasConceptScore W2580451850C54355233 @default.
• W2580451850 hasConceptScore W2580451850C71924100 @default.
• W2580451850 hasConceptScore W2580451850C86803240 @default.
• W2580451850 hasLocation W25804518501 @default.
• W2580451850 hasOpenAccess W2580451850 @default.
• W2580451850 hasPrimaryLocation W25804518501 @default.
• W2580451850 hasRelatedWork W2005971817 @default.
• W2580451850 hasRelatedWork W2029368270 @default.
• W2580451850 hasRelatedWork W2052803486 @default.
• W2580451850 hasRelatedWork W2124371994 @default.
• W2580451850 hasRelatedWork W2166807441 @default.
• W2580451850 hasRelatedWork W2334514523 @default.
• W2580451850 hasRelatedWork W2358978455 @default.
• W2580451850 hasRelatedWork W2403410214 @default.
• W2580451850 hasRelatedWork W2414734517 @default.
• W2580451850 hasRelatedWork W2513330489 @default.
• W2580451850 hasRelatedWork W2531529535 @default.
• W2580451850 hasRelatedWork W2557094714 @default.
• W2580451850 hasRelatedWork W2559099489 @default.
• W2580451850 hasRelatedWork W2560599324 @default.
• W2580451850 hasRelatedWork W2576552777 @default.
• W2580451850 hasRelatedWork W2578686835 @default.
• W2580451850 hasRelatedWork W2578990141 @default.
• W2580451850 hasRelatedWork W2588501350 @default.
• W2580451850 hasRelatedWork W2590753376 @default.
• W2580451850 hasRelatedWork W2883409390 @default.
• W2580451850 isParatext "false" @default.
• W2580451850 isRetracted "false" @default.
• W2580451850 magId "2580451850" @default.
• W2580451850 workType "article" @default.